10/08/2024
This webinar will discuss the rationale behind updating the guidelines for cervical cancer screening in immunosuppressed women. We will delve into the methodological approach used to revise the guidelines and the key factors that necessitated the update. Next, we will present an overview of the latest evidence supporting the updated guidelines, highlighting the research studies, clinical trials, and case series that have informed the changes in cervical cancer screening recommendations for immunosuppressed women. This section will also focus on the implications of these findings for clinical practice. Finally, we will summarize the key conclusions drawn from the updatedguidelines and their impact on the management of cervical cancer screening in immunosuppressed women with an emphasis on the importance of adhering to these recommendations to improve patient outcomes and reduce the burden of cervical cancer in this vulnerable population.
Lisa Flowers, MD, MPH
Professor in the Department of Obstetrics and
Gynecology, Emory University School of Medicine;
Atlanta, Georgia, USA
Michael A. Gold, MD
Clinical Associate Professor in the Department of
Obstetrics and Gynecology at University of Oklahoma
School of Community Medicine; Tulsa, Oklahoma, USA
Anna-Barbara Moscicki, MD
Professor of Pediatrics at UCLA;
Los Angeles, California, USA
